CDSCO Panel Approves J&J’s Protocol Amendment Proposal For Amivantamab, Lazertinib combination
New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major Johnson & Johnson’s proposal for the protocol amendment of the fixed-dose combination ( FDC) anti-cancer drug Amivantamab Plus Lazertinib. This came after the firm presented protocol amendment 4 dated 14 November 2023 protocol No.73841937NSC3003. […]